Francesca M. Onidi
Cagliari, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Effectiveness and Safety of Risankizumab in Crohn Disease After Failure of a First Line of Advanced Therapy: A Long-Term, Real-Life Study.
Journal: American journal of therapeutics
Published: July 23, 2026
Effectiveness and Safety of Risankizumab in Crohn Disease After Failure of a First Line of Advanced Therapy: A Long-Term, Real-Life Study.
Journal: American journal of therapeutics
Published: July 23, 2026
Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort Study.
Journal: Advances in therapy
Published: February 11, 2026
Upadacitinib's Effectiveness and Safety as a Second- or Third-Line Therapy in Patients with Ulcerative Colitis: Data from a Real-World Study.
Journal: Journal of clinical medicine
Published: August 27, 2025
Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world study.
Journal: Intestinal research
Published: April 29, 2025
Clinical and Genetic Characteristics of Pediatric Patients with Inflammatory Bowel Disease Transitioning to Adult Medicine: A Single-Center Ten-Year Experience.
Journal: Journal of clinical medicine
Published: March 25, 2025
Long-Term Effectiveness and Safety of Ustekinumab in Crohn's Disease: Results from a Large Real-Life Cohort Study.
Journal: Journal of clinical medicine
Published: September 23, 2024
Efficacy of a Preparation based on Symbiotic Association Between Inulin, FOS, L. rhamnosus GG, Bromelin, Boswellia, Vitamin D3, Quercetin and L-tryptophan in Mild-to-Moderate Ulcerative Colitis: A Pilot Retrospective Multicenter Study.
Journal: Reviews on recent clinical trials
Published: July 03, 2024
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study.
Journal: Expert opinion on biological therapy
Published: January 22, 2024
Ustekinumab in the Treatment of Inflammatory Bowel Diseases: Evolving Paradigms.
Journal: Journal of clinical medicine
Published: January 18, 2024
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study.
Journal: Expert opinion on pharmacotherapy
Published: June 26, 2023
Adalimumab biosimilar ABP 501 is equally effective and safe in long-term management of inflammatory bowel diseases patients when used as first biologic treatment or as replace of the ADA originator for a non-medical reason.
Journal: Frontiers in gastroenterology (Lausanne, Switzerland)
Published: May 06, 2023
Last Updated: 09/26/2026